Journal of Traditional and Complementary Medicine · 2024 · 10 citations · 38 references
PharmacyMedicinal ChemistryPharmacologyBioavailabilityDrug DiscoveryMolecular PharmacologyBlood-brain Barrier DeliveryBlood-brain Barrier PharmacologyMigraine PharmacotherapyNanoparticle DesignNeuroprotectionSolubility OptimizationAnti-inflammatory NeuropharmacologyAnti-inflammatory PharmacokineticsCalcitonin Gene-related Peptide Monoclonal AntibodiesCalcitonin Gene-related Peptide PhysiologyLow SolubilityMigraine PharmacologyPeptide InteractionsTherapeutic Target Identification
Background: Luteolin, a natural flavonoid, exhibits antioxidant and anti-inflammatory properties and has been investigated for potential health benefits. Its focus on migraine management arises from its ability to mitigate neuroinflammation, a key factor in migraine attacks. Methods: pkCSM and Swiss ADME were employed to assess luteolin's pharmacokinetic properties, revealing challenges such as low water solubility and limited skin permeability. OSIRIS Property Explorer is used to check the toxicity. Ligand binding simulations indicated luteolin's potential to interact with calcitonin gene related peptide proteins, crucial in migraine pathophysiology. DisGeNet identified common targets related to migraine, with subsequent network analysis emphasizing promising targets. Results and Discussion: Luteolin demonstrated good intestinal absorption but faced BBB limitations, suggesting a potential for oral administration but questioning direct brain impact. Nanoformulation was proposed to address solubility challenges, emphasizing the need for in vivo validation. The highest binding affinity with CGRP proteins PDBID: 6PFO (-7.63 kcal/mol) suggested a potential for migraine treatment, requiring empirical confirmation. Enrichment network analysis illustrated luteolin's potential in migraine treatment, emphasizing key targets such as PTGS2, AKT1, ESR1, MMP2, and MMP9. Luteolin shows promise for migraine management, evident in its pharmacokinetic, toxicological profiles, and interactions with CGRP proteins. Challenges like low solubility suggest the need for nanoformulations and empirical validation. Target identification and network analysis offer insights, highlighting potential therapeutic avenues in migraine treatment. Conclusion: Luteolin holds promise in migraine management, necessitating further research for translation into effective interventions, considering its neuroprotective potential in broader neurological conditions.
38
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina, Joel R. Saper, Roger Cady et al. · Cephalalgia · 2020 · 397 citations · Full text
Efficacy and safety of eptinezumab in patients with chronic migraine
Richard B. Lipton, Peter J. Goadsby, Jeff Smith et al. · Neurology · 2020 · 392 citations · Full text
Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 392 citations